Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium

HUNTINGTON BEACH, California and AMSTERDAM, December 8 - Agendia, a world leader in molecular cancer diagnostics,
announced today that it will be presenting six studies focusing on
MammaPrint(R) at the 2009 San Antonio Breast Cancer Symposium (SABCS), one of
the premiere conferences in breast cancer research worldwide. The SABCS will
take place December 9-13, at the Henry B. Gonzalez Convention Center in San
Antonio, Texas, USA.

Agendia's studies to be presented at the SABCS further
establish the broad predictive and prognostic power of MammaPrint, the only
FDA-cleared breast cancer recurrence test available to patients and
physicians. Conference attendees can meet the Agendia team at booth #556.

Study results will be discussed at the following sessions:

Date: Thursday, December 10, 2009

Time: 5:30 pm - 7:30 pm

Poster presentation (102)

Combining Genomic Profiling (70 Gene-MammaPrint) with Nodal
Status Allows to Classify Patients with Primary Breast Cancer and Positive
Lymph Nodes (1-9) into Very Distinct Prognostic Subgroups That Could Help
Tailor Treatment Strategies

Saghatchian M, Mook S, Pruneri G, Viale G, Glas A, Eekhout I,
Delaloge S, van 't Veer L. Institut Gustave Roussy, Villejuif, France;
Netherlands Cancer Institute, Amsterdam, The Netherlands; European Institute
of Oncology, Milan, Italy; Agendia BV, Amsterdam, The Netherlands.

Date: Friday, December 11, 2009

Time: 7 am - 9 am

Poster presentation (2026)

Basal-, Luminal-, and HER2- Molecular Subtype, and the
MammaPrint 70-Gene Signature as Predictors of Response to Neoadjuvant
Chemotherapy (NCT) with Docetaxel, Doxorubicin, Cyclophosphamide (TAC), or AC
and Nab-Paclitaxel and Carboplatin +/- Trastuzumab in Patients (pts) with
Stage II-III and Inflammatory Breast Cancer (BC)

Somlo G, Lau S, Frankel P, Garberoglio C, Kruper L, Yen Y, Luu
T, Hurria A, Chung CT, Mortimer J, Yim J, Paz IBe, Krijgsman O, Delahaye L,
Stork-Sloots L, Bender R. City of Hope Comprehensive Cancer Center, Duarte,
CA; Agendia BV, Amsterdam, The Netherlands; Agenda, Inc., Huntington Beach,
CA.

Date: Saturday, December 12, 2009

Time: 7 am - 9 am

Poster presentation (4049)

The 70-Gene Profile (MammaPrint) Is an Independent Predictor
of Breast Cancer Specific Survival for Women 65 Years of Age or Older

Bedard PL, Mook S, Knauer M, Durbecq V, Bernard-Marty C, Glas
AM, Cardoso F, van 't Veer LJ. Jules Bordet Institute, Brussels, Belgium;
Netherlands Cancer Institute, Amsterdam, The Netherlands; TRANSBIG
Consortium, Brussels, Belgium; Agendia BV, Amsterdam, The Netherlands

Date: Sunday, December 13, 2009

Time: 7 am - 8:30am

Poster presentation (6131)

Molecular Subtype Profile Reveals Therapy Predictive Power

de Snoo FA, Krijgsman O, Roepman P, Bender RA, Glas AM.
Agendia BV, Amsterdam, The Netherlands; Agenda, Inc., Huntington Beach, CA..

Date: Sunday, December 13, 2009

Time: 7 am - 8:30am

Poster presentation (6146)

Biological Functions of Genes in the 70-Gene MammaPrint Tumor
Expression Profile Reflect Molecular Mechanism of Tumor Metastasis

Glas AM, Tian S, Roepman P, Krijgsman O, Van 't Veer LJ, de
Snoo F. Agendia BV, Amsterdam, The Netherlands; The Netherlands Cancer
Institute, Amsterdam, The Netherlands.

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test cleared by
the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro
diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and
analytical validation and reporting systems to ensure patient safety issues
are addressed. Highly accurate, MammaPrint identifies patients with early
metastasis risk - patients who are likely to develop metastases within five
years following surgery. Several authoritative studies have shown that
chemotherapy particularly reduces early metastasis risk. In planning
treatment, the MammaPrint test results provide doctors with a clear rationale
to assess the benefit of chemotherapy in addition to other clinical
information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited service
laboratory. Breast cancer recurrence assays currently marketed by other
manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution,
striving to bring more effective, individualized treatments within reach of
patients. Building on a cutting-edge genomics platform for tumor gene
expression profiling, the company's tests help physicians more accurately
tailor cancer treatments. Agendia markets three products, with several new
genomic tests under development. In addition, Agendia collaborates with
pharmaceutical companies to develop highly effective personalized drugs in
the area of oncology. Agendia is based in Huntington Beach, California, and
in Amsterdam, The Netherlands.

Media contacts: Hans Herklots, Head of Corporate Communications, Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile, hans.herklots at agendia.com. Valerie Delva, Account Executive, Ricochet Public Relations, +1-212-679-3300 x131 Office, vdelva at ricochetpr.com